Dichloroacetate solution
(DCA; SL1009)
DCA is an investigational therapy. This means it is still being tested and reviewed. Saol Therapeutics is working with the FDA on possible approval in the U.S. It is not approved in Australia.
Study details
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency (NCT02616484).
Manufacturer
Saol Therapeutics Inc
Types of mito
Pyruvate dehydrogenase complex deficiency (PDCD)
Which people with mito might this therapy help?Â
Some children with genetically confirmed Pyruvate dehydrogenase complex deficiency (PDCD).
DCA is designed to help the pyruvate dehydrogenase complex work better. This may help mitochondria make more energy and reduce lactic acid build-up in some people with PDCD.
If approved, DCA would be used with a genetic test to help decide the dose. This test checks how quickly a person is likely to process DCA. The aim is to reduce side effects, such as peripheral neuropathy, which is nerve damage that can cause pain, weakness, numbness or tingling.
What research has been done on this therapy?Â
SL1009 has been studied in a Phase 3 clinical trial in children with PDCD. The study tested DCA compared with placebo.
Clinical trial information
Study name
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency (NCT02616484).
Location
The Phase 3 study was set up across sites in the United States. There are no Australian sites.
Who is funding the study?
Saol Therapeutics Inc.
This study is testing whether DCA is safe and whether it may help children with PDCD.
The study uses a daily survey completed by a parent or carer to measure changes in movement skills. It also looks at lactate levels in the blood.
Important information
Find out more
Emerging therapies for mito
Learn about developing therapies and opportunities to take part in research.
Clinical trials explained
A guide to help understand participation and make informed decisions.